Nuvation Bio Inc (NUVB)
2.57
-0.12
(-4.46%)
USD |
NYSE |
Apr 18, 16:00
2.57
0.00 (0.00%)
After-Hours: 17:12
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 562.95M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 48.62% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 0.9303 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs). |
URL | https://www.nuvationbio.com |
Investor Relations URL | https://investors.nuvationbio.com/ |
HQ State/Province | New York |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 03, 2024 (est.) |
Last Earnings Release | Feb. 29, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs). |
URL | https://www.nuvationbio.com |
Investor Relations URL | https://investors.nuvationbio.com/ |
HQ State/Province | New York |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 03, 2024 (est.) |
Last Earnings Release | Feb. 29, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |